Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancers (BCs) and lacks estrogen receptor (ER) and progesterone receptor (PR) expression as well as human epidermal growth factor receptor 2 (HER2) amplification. Here, ESR1 is linked to triple-negative breast carcinoma.